We provide comprehensive preclinical evidence supporting the therapeutic potential of the traditional Chinese medicine (TCM)-derived formulation NeuproGemp in attenuating Alzheimer’s disease (AD)-like phenotypes in the APP/PS1 transgenic mouse model. This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.